Real-world Evidence of Improved Patient Outcomes With Reslizumab in Non-exacerbating Patients With Severe Eosinophilic Asthma (SEA): A Subgroup Analysis

Outcomes from a real-world study reflected the effectiveness of reslizumab in U.S. clinical practice. Here we present the subgroup analyses of patients without CAEs, pre- and post-reslizumab treatment. Patient-level data on adults with SEA receiving reslizumab for ≥7 months were collated via a multicenter, retrospective chart review. Patient outcomes during the 6 month pre- and post-reslizumab initiation included FEV1 percent predicted (FEV1PP),...